Group 1 - The Hang Seng Medical Index ETF has shown active trading with a turnover of 17.71% and a transaction volume of 46.90 million yuan, indicating a vibrant market activity [3] - Over the past six months, the Hang Seng Medical Index ETF has experienced a significant growth in scale, increasing by 51.07 million yuan, ranking first among comparable funds [3] - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index ETF is 26.52, which is in the 8th percentile over the past three years, indicating a historical low valuation [3] Group 2 - As of May 29, the number of globally approved new drugs in China has reached 54, with 34 being domestic innovative drugs and 20 imported, showing a strong growth in domestic innovation [3] - The approval of domestic innovative drugs in 2024 is projected to be 37, while the number approved in the first half of this year is close to last year's total, highlighting a rapid increase in innovation [3] - Institutions believe that the competitiveness of domestic innovative drugs in the global market is rising, and international investors are increasingly confident in Chinese innovative pharmaceutical companies [4]
国产创新药全球市场竞争力不断提升，恒生医疗指数ETF(159557)盘中涨近5%
Sou Hu Cai Jing·2025-06-09 03:26